UPDATE 1-Melanoma patients live longer on Roche's Avastin
* First time a trial has shown melanoma survival benefit
* News may trigger early prescribing by melanoma specialists
* Could offer potential $500 million new market for Roche
(Adds background, analysts, more detail)
BERLIN, Sept 21 (Reuters) - Patients with melanoma, a notoriously difficult to treat cancer of the skin, live longer when given Roche's (ROG.VX) drug Avastin, according to a scientific abstract from Europe's top cancer meeting.
The median overall survival in a Phase II trial was 12.6 months for Avastin plus standard chemotherapy, significantly more than the 8.6 months seen with chemotherapy on its own.
"This is the first randomised placebo-controlled trial in metastatic melanoma to demonstrate a statistically significant and clinically meaningful improvement in OS (overall survival)," investigator Steven O'Day reported.
The finding, which will be reported in full at the ECCO-ESMO cancer conference in Berlin on Wednesday, is likely to boost interest in Avastin among melanoma specialists, who may use it on a so-called "off label" basis before formal approval.
While melanoma accounts for only a small percentage of skin cancers, it is responsible for most skin cancer deaths. The disease is characterised by the uncontrolled proliferation of pigment-producing skin cells called melanocytes.
Over-exposure to sunlight is to blame for at least two-thirds of cases as DNA in sunburnt skin cells becomes damaged, leading to the genetic mutations.
Avastin is already a blockbuster and a key driver for Roche, with global sales of 5.2 billion Swiss francs ($5.02 billion) in 2008 as a treatment for colon, lung and breast cancers.
Analysts said the results of its trial in melanoma represented the first ever survival benefit for a so-far unmet need in cancer.
It is possible Roche may decide to apply for a licence for Avastin in melanoma based on these results alone, they said, avoiding the need to go through full final phase trials and opening up a potential $500 million new market. ($1=1.036 Swiss Franc) (Reporting by Ben Hirschler and Kate Kelland; editing by David Cowell)
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video